ArticleStem cell research & therapy2025
Therapeutic potential of hAMSCs in ligament regeneration: insights from the UCA1-miR-16-5p-FGF2 pathway.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWith the growing demand for physical activity, there is a large population of patients suffering from ligament injuries, characterized by a high incidence and a need for early return to sports. A critical issue to address is how to promote the repair of damaged ligaments at the microscopic level and facilitate tendon-bone healing post-surgery. Among various studies, hAMSCs ( human amniotic mesenchymal stem cells ) have shown strong differentiation capabilities, and by inducing their differentiation into ligament cells, they may promote tendon-bone healing.
methodsHuman amniotic mesenchymal stem cells were extracted and cultured from human amniotic tissues. The cells were identified as mesenchymal stem cells through toluidine blue, safranin O, and oil red O staining. The differentiation of these cells into ligament cells was assessed by detecting relevant markers, including protein expression via Western blot and mRNA levels through qPCR(Quantitative polymerase chain reaction). Additionally, we used dual-luciferase reporter assays to verify the targeted interactions between lncRNA UCA1 and miR-16-5p, as well as between miR-16-5p and mRNA FGF2.
resultsOverexpression of lncRNA UCA1 and mRNA FGF2 increased the expression levels of Type I collagen (COL 1), Type III collagen (COL 3), and mohawk homeobox (MKX), key markers of ligament differentiation. LncRNA UCA1 was found to bind with miR-16-5p. The miR-16-5p can target mRNA FGF2, forming a regulatory axis that controls the differentiation of hAMSCs into ligament cells. Furthermore, we discovered that upregulation of miR-16-5p could inhibit the regulatory effects of overexpressed lncRNA UCA1 and mRNA FGF2 on mesenchymal stem cells.
conclusionIn this study, we identified the presence of a ceRNA network involving the UCA1-miR-16-5p-FGF2 axis in hAMSCs. By regulating the key components of this axis, we can modulate the differentiation of hAMSCs into ligament cells, providing a potential therapeutic strategy for promoting tendon-bone healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.